J. Lin

435 citations

18 papers · 286 · h-index 10

Impact in

Cancer Research
- Cancer, Lipids, and Metabolism
Endocrinology, Diabetes and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in

Surgery 8
- Lipoproteins and Cardiovascular Health 7
Oncology 8
- Cancer Immunotherapy and Biomarkers 6

Co-authors: Arvind Shah (8 shared papers)Amy O. Johnson‐Levonas (3 shared papers)Andrew M. Tershakovec (5 shared papers)Philippe Brudi (2 shared papers)Lawrence A. Leiter (3 shared papers)John R. Guyton (2 shared papers)Mary E. Hanson (4 shared papers)D. J. Betteridge (1 shared paper)
Journals: Annals of Oncology (5 papers)International Journal of Clinical Practice (4 papers)Diabetes Obesity and Metabolism (3 papers)Journal of Thoracic Oncology (1 paper)Oral Oncology (1 paper)
Partner nations: United States Canada Italy

In The Last Decade

J. Lin

18 papers receiving 276 citations

Peers

Countries citing papers authored by J. Lin

Since Specialization

Citations

This map shows the geographic impact of J. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Lin more than expected).

Fields of papers citing papers by J. Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Lin. The network helps show where J. Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Lin Line = papers co-authored together J. Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials Diabetes Obesity and Metabolism ·Lawrence A. Leiter, D. J. Betteridge, Michel Farnier, John R. Guyton, J. Lin, Arvind Shah, Amy O. Johnson‐Levonas, Philippe Brudi	2011	56
2	Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study International Journal of Clinical Practice ·Dieter Lütjohann, Klaus von Bergmann, Waheeda Sirah, Geraldine Macdonell, Amy O. Johnson‐Levonas, Arvind Shah, J. Lin, Aditi Sapre, (unknown)	2008	47
3	Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients Atherosclerosis ·Olivier Descamps, Joanne E. Tomassini, J. Lin, (unknown), Arvind Shah, Philippe Brudi, Mary E. Hanson, Andrew M. Tershakovec	2015	32
4	Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither Diabetes Obesity and Metabolism ·Scott Conard, Harold Bays, Lawrence A. Leiter, Steve Bird, J. Lin, Mary E. Hanson, Arvind Shah, Andrew M. Tershakovec	2009	29
5	Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407 Annals of Oncology ·Steven Powell, Delvys Rodríguez‐Abreu, Corey J. Langer, Ali Tafreshi, L. Paz-Ares, Hans‐Georg Kopp, Jerónimo Rafael Rodríguez‐Cid, Dariusz M. Kowalski, Ying Cheng, Takayasu Kurata, Mark M. Awad, J. Lin, Bin Zhao, M. Catherine Pietanza, Bilal Piperdi, M.C. Garassino	2019	23
6	Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 Annals of Oncology ·Aaron S. Mansfield, Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, D.-W. Kim, Silvia Novello, Miyako Satouchi, Yi‐Long Wu, Edward B. Garon, Martin Reck, Andrew Robinson, Ayman Samkari, Bilal Piperdi, Victoria Ebiana, J. Lin, Tony Mok	2019	21
7	FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC Journal of Thoracic Oncology ·Byoung Chul Cho, Yi‐Long Wu, G. Lopes, Iveta Kudaba, Dariusz M. Kowalski, H.Z. Turna, Gilberto de Castro, Christian Caglevic, L. Zhang, Bogusława Karaszewska, К. К. Лактионов, Vichien Srimuninnimit, Igor Bondarenko, Kazuo Kubota, Lei Yin, J. Lin, Francis Ribeiro de Souza, Tony Mok	2021	20
8	Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome Diabetes Obesity and Metabolism ·Sergio Fazio, John R. Guyton, J. Lin, Joanne E. Tomassini, Arvind Shah, Andrew M. Tershakovec	2010	14
9	Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks International Journal of Clinical Practice ·Peter P. Tóth, Doralisa Morrone, William S. Weintraub, Mary E. Hanson, Robert S. Lowe, J. Lin, Arvind Shah, Andrew M. Tershakovec	2012	10
10	A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet* International Journal of Clinical Practice ·Leiv Ose, Amy O. Johnson‐Levonas, Rafael Reyes, J. Lin, Arvind Shah, Diane L. Tribble, (unknown), (unknown)	2007	9
11	Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence Oral Oncology ·Kevin J. Harrington, Ezra E.W. Cohen, Denis Soulières, José Dinis, Lisa Licitra, Myung‐Ju Ahn, Ainara Soria, J.-P. Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Ramona F. Swaby, J. Lin, Joy Yang Ge, Nati Lerman, Christophe Le Tourneau	2023	7
12	44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation Annals of Oncology ·S-A. Im, Javier Cortés, Oleg Lipatov, Anthony Gonçalvès, KS Lee, Peter Schmid, Kenji Tamura, Laura Testa, I Witzel, Shoichiro Ohtani, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, J. Lin, Vassiliki Karantza, Jaime Mejia, Eric P. Winer	2020	4
13	Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin International Journal of Clinical Practice ·Lawrence A. Leiter, Harold Bays, Scott Conard, J. Lin, Mary E. Hanson, Arvind Shah, Andrew M. Tershakovec	2010	4
14	EC-SpMM: Efficient Compilation of SpMM Kernel on GPUs J. Lin, Honghe Zhang, Xiaolong Shi, Jingwei Sun, Xianzhi Yu, Jun Yao, Guangzhong Sun	2023	3
15	LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC) Annals of Oncology ·Brian I. Rini, C. Suarez Rodriguez, Laurence Albigès, K. Jalkanen, G.A. De Velasco Oria, Mauricio Burotto, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, (unknown), Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, B. Venugopal, J. Lin, R. Perini, Donna Vickery, Toni K. Choueiri, T.B. Powles	2024	3
16	LO-SpMM: Low-cost Search for High-performance SpMM Kernels on GPUs ACM Transactions on Architecture and Code Optimization ·J. Lin, Jingwei Sun, Xiaolong Shi, Honghe Zhang, Xianzhi Yu, Xinzhi Wang, Jun Yao, Guangzhong Sun	2024	2
17	106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study Immuno-Oncology Technology ·Richard Greil, Barbara Burtness, Simon Laban, Irene Braña, R. Mesía Nin, Thorsten Fuereder, Åse Bratland, Lisa Licitra, Tamara Rordorf, Amanda Psyrri, Aron Popovtzer, Brett Hughes, Makoto Tahara, J. Lin, (unknown), Nati Lerman, Kevin J. Harrington	2023	1
18	6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407 Annals of Oncology ·Ying Cheng, James Chih‐Hsin Yang, Isamu Okamoto, L. Zhang, Jie Hu, Dan Wang, Chengping Hu, Jianying Zhou, Lin Wu, L. Cao, Jing Liu, H. Zhang, Hong Sun, Z. Wang, Hongjun Gao, Yingjie Yan, Song Xiao, J. Lin, M. Catherine Pietanza, Takayasu Kurata	2021	1

About J. Lin

J. Lin is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Economics and Econometrics and Cancer Research, having authored 18 papers that have together received 286 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Pharmaceutical Economics and Policy (3 papers), Cancer Genomics and Diagnostics (2 papers), Computational Drug Discovery Methods (2 papers) and Diabetes Treatment and Management (2 papers). The work is most often cited by research in Cancer Research (70 citations), Endocrinology, Diabetes and Metabolism (74 citations), Surgery (174 citations), Oncology (94 citations) and Pulmonary and Respiratory Medicine (74 citations). J. Lin has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Arvind Shah, Amy O. Johnson‐Levonas, Andrew M. Tershakovec, Philippe Brudi, Lawrence A. Leiter, John R. Guyton, Mary E. Hanson, D. J. Betteridge, Michel Farnier and Joanne E. Tomassini. Their work appears in journals such as Annals of Oncology, International Journal of Clinical Practice, Diabetes Obesity and Metabolism, Journal of Thoracic Oncology and Oral Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

J. Lin

Impact in

Papers in i

In The Last Decade

J. Lin

Peers

Countries citing papers authored by J. Lin

Fields of papers citing papers by J. Lin

All Works

About J. Lin

Explore authors with similar magnitude of impact

Papers in